119 related articles for article (PubMed ID: 25682700)
1. Enhancement of Pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin.
Bucki R; Cruz K; Pogoda K; Eggert A; Chin L; Ferrin M; Imbesi G; Hadjiliadis D; Janmey PA
J Cyst Fibros; 2015 Sep; 14(5):587-93. PubMed ID: 25682700
[TBL] [Abstract][Full Text] [Related]
2. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum.
Tang JX; Wen Q; Bennett A; Kim B; Sheils CA; Bucki R; Janmey PA
Am J Physiol Lung Cell Mol Physiol; 2005 Oct; 289(4):L599-605. PubMed ID: 15964901
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
4. Gelsolin activates DNase I in vitro and cystic fibrosis sputum.
Davoodian K; Ritchings BW; Ramphal R; Bubb MR
Biochemistry; 1997 Aug; 36(32):9637-41. PubMed ID: 9289015
[TBL] [Abstract][Full Text] [Related]
5. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin.
Vasconcellos CA; Allen PG; Wohl ME; Drazen JM; Janmey PA; Stossel TP
Science; 1994 Feb; 263(5149):969-71. PubMed ID: 8310295
[TBL] [Abstract][Full Text] [Related]
6. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4.
Kater A; Henke MO; Rubin BK
Ann N Y Acad Sci; 2007 Sep; 1112():140-53. PubMed ID: 17496063
[TBL] [Abstract][Full Text] [Related]
7. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin.
Weiner DJ; Bucki R; Janmey PA
Am J Respir Cell Mol Biol; 2003 Jun; 28(6):738-45. PubMed ID: 12600826
[TBL] [Abstract][Full Text] [Related]
8. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease.
Sheils CA; Käs J; Travassos W; Allen PG; Janmey PA; Wohl ME; Stossel TP
Am J Pathol; 1996 Mar; 148(3):919-27. PubMed ID: 8774146
[TBL] [Abstract][Full Text] [Related]
9. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA
J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802
[TBL] [Abstract][Full Text] [Related]
10. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321
[TBL] [Abstract][Full Text] [Related]
11. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics.
Perks B; Shute JK
Am J Respir Crit Care Med; 2000 Nov; 162(5):1767-72. PubMed ID: 11069810
[TBL] [Abstract][Full Text] [Related]
12. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
Broughton-Head VJ; Smith JR; Shur J; Shute JK
Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
[TBL] [Abstract][Full Text] [Related]
13. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.
Bucki R; Byfield FJ; Janmey PA
Eur Respir J; 2007 Apr; 29(4):624-32. PubMed ID: 17215317
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
16. DNA-fragmentation is a source of bactericidal activity against Pseudomonas aeruginosa.
Bhongir RK; Kasetty G; Papareddy P; Mörgelin M; Herwald H; Egesten A
Biochem J; 2017 Feb; 474(3):411-425. PubMed ID: 27784762
[TBL] [Abstract][Full Text] [Related]
17. Development of an analytical HPLC methodology to study the effects of thymosin β4 on actin in sputum of cystic fibrosis patients.
Badamchian M; Damavandy AA; Goldstein AL
Ann N Y Acad Sci; 2012 Oct; 1270():86-92. PubMed ID: 23050822
[TBL] [Abstract][Full Text] [Related]
18. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
19. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis.
Reid DW; Carroll V; O'May C; Champion A; Kirov SM
Eur Respir J; 2007 Aug; 30(2):286-92. PubMed ID: 17504792
[TBL] [Abstract][Full Text] [Related]
20. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
